Apogee Therapeutics, Inc. (APGE)
85.49
+2.77
(+3.35%)
USD |
NASDAQ |
Jun 11, 12:30
Apogee Therapeutics Debt to Equity Ratio : 0.0064 for March 31, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| March 31, 2026 | 0.0064 |
| December 31, 2025 | 0.0098 |
| September 30, 2025 | 0.0168 |
| June 30, 2025 | 0.0175 |
| March 31, 2025 | 0.0175 |
| December 31, 2024 | 0.0165 |
| September 30, 2024 | 0.0165 |
| Date | Value |
|---|---|
| June 30, 2024 | 0.0053 |
| March 31, 2024 | 0.0022 |
| December 31, 2023 | 0.0054 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Evommune, Inc. | 0.0299 |
| Cogent Biosciences, Inc. | 0.3927 |
| Kymera Therapeutics, Inc. | 0.0523 |
| Erasca, Inc. | 0.1168 |
| GRAIL, Inc. | 0.0204 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 1.294B |
| Total Liabilities (Quarterly) | 37.86M |
| Shareholders Equity (Quarterly) | 1.256B |
| Current Ratio | 32.59 |
| Net Debt Paydown Yield | 0.01% |